A novel genetic approach was reported by Pandey et al. [62], who found that homozygous carriers of GM17, a variant of the IgG1 antibody gene, have a fourfold greater risk of AD than have non-carriers, independently of APOE-ε4 risk. This evidence concerns the gene APOE and Alzheimer disease.